DNTH · Dianthus Therapeutics, Inc. /DE/
$88.34
+0.29 (+0.33%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the "issuance date") As of the issuance date, the Company expects that its existing cash, cash equivalents and investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date.”View the 10-Q filed Aug 4, 2026
Market Cap
$5.23B
Shares
55.93M
Volume · Oct 1
31.41K
Avg daily vol (3M)
833.35K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$88.05
Open$88.19
Day$87.58–90.71
52W close$32.92–115.96
Avg vol 30d785K
Short int8.8M · 15.8% float · 14.4d
Short vol67%
Last earningsMar 9, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 4
Up next
filed Aug 4, 2026
call held Mar 9, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+120.4%
Trailing year
Short interest
15.8%
Latest settlement · 14.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
−16%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
66%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
−4%
trailing
YTD return
+114%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $105 › 200d $81 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +64 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.79% of float · ▲ +4.7% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
272 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
−67%
Y/Y
EPS growth
−65%
Y/Y
Free cash flow
$-129.4M
Quant / Vol
risk profile
Volatility
61%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
−16%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
66%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $105 › 200d $81 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +64 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.79% of float · ▲ +4.7% MoM · 14.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
272 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $33
Now $88 · 66%
Range high $116
vs 200-day avg +9%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNTH
this stock
Dianthus Therapeutics, Inc. /DE/
|
$5.23B | +113.7% | -67.3% | — | 15.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNTH | -5.8% | -17.4% | -3.9% | -16.6% | +113.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -5.1% | -17.5% | -16.1% | -16.1% | +101.8% |